With sentiment turning against the biotech sector in the public markets, leading European life science venture capital firm Forbion has put together a new fund that could be worth €600m to tap into some of the continent's promising players that are searching for financing for their late-stage projects.
The VC has announced the initial close of €470m ($500m) for its second growth fund to invest in late-stage European...








